The Pharma Data

NOVEMBER 6, 2020

Food and Drug Administration (FDA) permitted marketing of a new device intended for the temporary reduction of sleep disturbance related to nightmares in adults 22 years or older who suffer from nightmare disorder or have nightmares from post-traumatic stress disorder (PTSD). Nightware is not a standalone therapy for PTSD.

FDA 40

FDA Marketing Therapies Treatment 40

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif.

Therapies 52

Therapies Production Government Disease 52

PPD

OCTOBER 12, 2023

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.

Laboratories 52

Laboratories Protein Expression Clinical Trials Pharmacokinetics 52

The Pharma Data

SEPTEMBER 15, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. Balance risk and innovation in regulation using new digital-therapy products.

Regulations 52

Regulations Production Therapies Treatment 52

The Pharma Data

DECEMBER 22, 2020

Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy. Outside of Japan , Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. SAN MATEO, Calif. , ” About Rakuten Medical, Inc.

Clinical Trials 52

Clinical Trials Therapies Trials Production 52

PPD

SEPTEMBER 27, 2023

Biopharma and biotech companies can overcome these common challenges by partnering with a clinical research organization that integrates data usage, leverages new technologies and embraces innovative approaches to advance clinical trials and quickly bring therapies to market.

Drug Development 52

Drug Development Clinical Trials Clinical Research Drugs 52

PPD

MARCH 26, 2024

Backed by a 25-year legacy of FSP support for clinical and marketed products, we know what it takes to deliver customized solutions tailored to the unique needs of each client, providing much-needed resource flexibility, reliability and continuity. Stay ahead of the competition with the latest FSP insights and trends.

Clinical Research 98

Clinical Research Clinical Development Pharmaceutical Companies Drug Development 98

Drug Channels

MAY 9, 2022

Emily Phillips, Reimbursement, Patient Advocate, & Government Affairs Leader Melissa Beatty, Director, Patient Services and Reimbursement, CTI Bio Pharma Chad Bower, Executive Director, Field Reimbursement & Oncology Solutions, US Market Access, Daiichi Sankyo, Inc. Download the full agenda and save your seat today!

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Pharmaceuticals Government 75

Drug Channels

OCTOBER 19, 2020

You can download the complete agenda here. Download the agenda to plan your sessions and wrap up your week armed with critical updates and valuable takeaways. Visit www.informaconnect.com/trade-channel for further details and to register. Visit www.informaconnect.com/trade-channel for further details and to register.

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

Drug Channels

NOVEMBER 8, 2020

You can download the complete agenda here. Visit www.informaconnect.com/trade-channel for further details and to register. Drug Channels readers will save $200 off the standard rate when they use code KTP933 and register prior to November 20th.*. Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more!

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Pharmaceuticals 52

Perficient: Drug Development

AUGUST 20, 2023

Virtual Therapists and Chatbots Online platforms and apps offering virtual therapy sessions or AI-driven chatbots provide accessible and immediate support to individuals who may find traditional therapy challenging or expensive.

Therapies 52

Therapies Production Marketing 52

Perficient: Drug Development

AUGUST 8, 2023

Here are some ways to provide support: Speech Therapy Speech therapy is a specialized field that plays a crucial role in helping individuals overcome speech disabilities and communication challenges.

Therapies 52

Therapies Production Marketing 52

The Pharma Data

JANUARY 20, 2021

The first target market for CureLab Veterinary’s patented DNA therapeutics will be to treat cancer in dogs and cats. “Receiving market authorization through the USDA approval process is cost efficient and relatively fast. View original content to download multimedia: [link]. BOSTON , Jan. About CureLab Oncology.

DNA 52

DNA Therapies International Production 52

The Pharma Data

DECEMBER 27, 2020

C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy – Catalyst PT. “There is a trend within radiation therapy towards high precision treatments. STOCKHOLM , Dec. The other sites will follow in 2021 and 2022. About C-RAD.

Treatment 52

Treatment Therapies Regulations Marketing 52

PPD

OCTOBER 2, 2024

To support these functions, PPD™ Functional Service Partnership (FSP) Clinical Operations solutions harness the full range of innovative technologies, applying extensive skill and expertise to empower our customers to bring therapies to market quickly and within budget.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Trials 52

The Pharma Data

DECEMBER 9, 2020

10, 2020 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi ) (STO: SOBI) today announced that a Marketing Authorization Application for emapalumab has been accepted for review in China. In the US, emapalumab is the first therapy approved by the US Food & Drug Administration (FDA) for primary HLH. STOCKHOLM , Dec.

FDA Approval 40

FDA Approval Therapies FDA Treatment 40

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 118

Therapies DNA Virus Clinical Trials 118

Drug Channels

AUGUST 14, 2021

In such a fluid year for medication access and affordability, join influential stakeholders as they innovate on copay program design and operations, identify key trends in market access, patient affordability and the future of the drug pricing and analyze the impact of cost sharing on out of pocket costs and high deductible health plans.

Government 40

Government Regulations Therapies Drugs 40

The Pharma Data

OCTOBER 20, 2020

CureLab intends to receive market approval for commercialization in the GCC region. The GCC market is lucrative, and the tax policies in Dubai are attractive. View original content to download multimedia: [link]. ” About Elenagen CureLab’s lead product, Elenagen , is a DNA encoding gene called p62/SQSTM1. .”

DNA 52

DNA Hospitals International Trials 52

Drug Channels

OCTOBER 26, 2020

You can download the complete agenda here. Download the agenda to plan your sessions and wrap up your week armed with critical updates and valuable takeaways. Drug Channels readers will save $300 off the standard rate when they use code GNB425 and register prior to October 30th.*.

Government 40

Government Pharmaceuticals Science Production 40

The Pharma Data

NOVEMBER 4, 2020

The aim is to sign 1-2 new license agreements per year, with focus on orthopedic and dental implants, as well as different types of products for the urinary tract, blood stream and airways for the global market. We now have a broader base and better market coverage in Europe , the Middle East , India , Southeast Asia and China.

Licensing 52

Licensing Licensing Production Marketing 52

The Pharma Data

NOVEMBER 3, 2020

m (-), including US launch of the scientifically proven digital therapies deprexis® and vorvida®. These changes in prioritization have been made to ensure we have all the resources needed to secure a successful launch of the digital therapies and to ensure OX124 development is finalized and meet FDA’s requirement.

Therapies 52

Therapies Production Pharmaceuticals Marketing 52

The Pharma Data

JANUARY 7, 2021

The ADSs have been approved for listing on The Nasdaq Global Market and are expected to begin trading on January 8, 2021 under the ticker symbol “GRCL “ The offering is expected to close on January 12, 2021 subject to the satisfaction of customary closing conditions. SUZHOU and SHANGHAI, China , Jan.

Therapies 52

Therapies Marketing Production Treatment 52

The Pharma Data

DECEMBER 1, 2020

IsoPlexis’ Single-Cell Intracellular Proteome solution has been recognized for its impact on the development of better targeted and edited therapies and its potential to innovate and accelerate medical research. MEDIA CONTACT: Jon Chen VP of Marketing info@isoplexis.com. BRANFORD, Conn. , BRANFORD, Conn. ,

Therapies 52

Therapies Disease Science Research 52

The Pharma Data

DECEMBER 14, 2020

The global GBM treatment market is projected to reach $3.3 representing the largest market. The effectiveness of standard therapy with TMZ is limited because the response of GBM to TMZ is dependent upon the expression of the DNA repair enzymatic protein, O 6 -alkylguanine DNA alkyltransferase (MGMT).

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients. About ImaginAb. ImaginAb Inc. Source link.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 11, 2020

a clinical AI analytics platform, has partnered with iNDX.Ai , a data analytics and translation research platform, to launch a Covid-19 command center to accelerate research and development programs for therapies to prevent and treat Covid-19. Saama Technologies, Inc. , Source link.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Hospitals 52

The Pharma Data

NOVEMBER 24, 2020

In prostate cancer there is currently no other therapy available for patients to prevent cancer recurrence. Currently, these patients undergo only surveillance and have no access to preventive therapy. Only when patients are diagnosed with recurring and now metastatic cancer, are they again eligible for therapy such as hormone therapy.

FDA 40

FDA Clinical Trials Drugs Therapies 40

The Pharma Data

JANUARY 13, 2021

At Usona, Mr. Barrow was responsible for launching the Phase 2 clinical program for psilocybin in the treatment of Major Depressive Disorder and for obtaining Breakthrough Therapy Designation for the program at FDA. MindMed Co-CEO J.R. About MindMed.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

JANUARY 31, 2021

An issue of SEK denominated senior unsecured callable floating rate bonds in the amount up to SEK 500 million , under a framework of SEK 1,000 million and with a tenor of four years (the “New Bonds”) may follow, subject to, inter alia, market conditions. CONTACT: This information was brought to you by Cision [link].

Production 40

Production Marketing Regulations Therapies 40

PPD

SEPTEMBER 25, 2023

Focusing on tailoring treatments to individual patients based on genetic, lifestyle and environmental factors, precision medicine offers more targeted and effective therapies while minimizing side effects. Successful market access and product update stems from valuable RWD and RWE regarding a product’s safety, effectiveness and value.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

The Pharma Data

DECEMBER 29, 2020

HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company was officially included into the Shenzhen-Hong Kong Stock Connect program (the “Hong Kong Stock Connect”). Ascentage Pharma (6855.HK)

Clinical Development 52

Clinical Development FDA Regulations Clinical Trials 52

Perficient: Drug Development

SEPTEMBER 26, 2023

While traditional therapies and interventions have proven beneficial, technology, particularly brain training apps, offers a new dimension of support. Challenges Faced by Individuals with Cognitive Disabilities Living with a cognitive disability can present numerous challenges for individuals and their families.

Production 52

Production Disease Therapies Research 52

The Pharma Data

DECEMBER 17, 2020

“We are pleased with the expeditious review and approval of our market authorization application for Buvidal by Swissmedic and that patients with opioid dependence in Switzerland will now have access to an effective long-acting treatment,” says Fredrik Tiberg , PhD, President & CEO of Camurus. LUND, Sweden , Dec.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

The Pharma Data

JANUARY 27, 2021

. A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study, all of whom were late stage and have failed conventional treatments, including several lines of rituximab-containing therapies. View original content to download multimedia: [link].

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 7, 2021

RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox , will present at the 39th Annual J.P. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. SAN MATEO, Calif. ,

Clinical Trials 52

Clinical Trials Therapies Trials Licensing 52

The Pharma Data

JANUARY 26, 2021

Previous human pharmacokinetic (PK) study showed significantly better PK profile when compared to market leading product. US market for overdose rescue medications. The following files are available for download: View original content: [link]. Patent protection until 2039.

Drugs 52

Drugs Pharmacokinetics Production FDA 52